Genmab — Earnings Release 2016

Apr 20, 2016

Company Announcement

-- Genmab improves financial guidance for 2016
-- Improvement driven by DARZALEX® sales
-- Rapid uptake of the product since launch

Copenhagen, Denmark; April 20, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN)
announced today that it is improving its financial guidance published on
February 17, 2016. The improvement is driven by the anticipation of increased
royalty income related to the sales of DARZALEX by Genmab’s collaboration
partner Janssen Biotech, Inc. and the rapid uptake of the product since launch.

“We are pleased to improve our 2016 financial guidance based on the robust
level of DARZALEX sales that we have seen since the product’s launch in
November 2015,” said Jan van de Winkel, Ph.D., Chief Executive Officer of
Genmab.

Outlook 2016

MDKK Revised Guidance Original Guidance

Revenue 925 – 975 825 – 875

Operating expenses (775) – (825) (775) – (825)

Operating income 125 – 175 25 – 75

Cash position at end of year* 3,400 – 3,500 3,300 – 3,400

*Cash, cash equivalents, and marketable securities

We expect our 2016 revenue to be in the range of DKK 925 – 975 million, an
increase of DKK 100 million compared to the previous guidance. Our projected
revenue for 2016 consists primarily of daratumumab milestones of DKK 400
million and DARZALEX royalties of DKK 300 – 350 million (previously DKK 200 –
250 million) that are based on an estimated USD 400 – 450 million of DARZALEX
sales in 2016 (previously USD 250 – 300 million). The remainder of the revenue
mainly consists of Arzerra® royalties, DuoBody® milestones, and non-cash
amortization of deferred revenue.

We anticipate that our 2016 operating expenses will remain in the range of DKK
775 – 825 million. The increased expense level from previous years is driven by
the additional investment in our pipeline of products, including the
advancement of tisotumab vedotin as well as HuMax®-AXL-ADC, HexaBody®-DR5/DR5,
DuoBody-CD3xCD20, and our other pre-clinical programs.

We expect the operating income for 2016 to be approximately DKK 125 - 175
million, an improvement of DKK 100 million, compared to the previous guidance
of DKK 25 - 75 million.

We are projecting a cash position at the end of 2016 of DKK 3,400 – 3,500
million, an improvement of DKK 100 million, compared to the previous guidance
of DKK 3,300 – 3,400 million.

In addition to factors already mentioned, the estimates above are subject to
change due to numerous reasons, including but not limited to the achievement of
certain milestones associated with our collaboration agreements; the timing and
variation of development activities (including activities carried out by our
collaboration partners) and related income and costs; Arzerra and DARZALEX
sales and corresponding royalties to Genmab; fluctuations in the value of our
marketable securities; and currency exchange rates. The financial guidance does
not include any potential proceeds from future warrant exercises and also
assumes that no significant agreements are entered into during 2016 that could
materially affect the results.

About DARZALEX® (daratumumab)
DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the
United States for the treatment of patients with multiple myeloma who have
received at least three prior lines of therapy, including a proteasome
inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a
PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody
(mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat
multiple myeloma. For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high
affinity to the CD38 molecule, which is highly expressed on the surface of
multiple myeloma cells. It is believed to induce rapid tumor cell death through
programmed cell death, or apoptosis,1,2 and multiple immune-mediated
mechanisms, including complement-dependent cytotoxicity,1,2 antibody-dependent
cellular phagocytosis3,4 and antibody-dependent cellular cytotoxicity.1,2 In
addition, daratumumab therapy results in a reduction of immune-suppressive
myeloid derived suppressor cells (MDSCs) and subsets of regulatory T cells
(Tregs) and B cells (Bregs), all of which express CD38. These reductions in
MDSCs, Tregs and Bregs were accompanied by increases in CD4+ and CD8+ T cell
numbers in both the peripheral blood and bone marrow.1

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive
worldwide license to develop, manufacture and commercialize daratumumab from
Genmab. Five Phase III clinical studies with daratumumab in relapsed and
frontline settings are currently ongoing, and additional studies are ongoing or
planned to assess its potential in other malignant and pre-malignant diseases
on which CD38 is expressed, such as smoldering myeloma, non-Hodgkin’s lymphoma
and a solid tumor indication.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin’s lymphoma.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody® platform which creates effector function enhanced antibodies.
The company intends to leverage these technologies to create opportunities for
full or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

1 DARZALEX Prescribing Information, November 2015.
2 De Weers et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal
Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors.
The Journal of Immunology. 2011; 186: 1840-1848.
3 Overdijk et al. Antibody-mediated phagocytosis contributes to the anti-tumor
activity of the therapeutic antibody daratumumab in lymphoma and multiple
myeloma. MAbs. 2015; 7: 311-321.
4 Khagi and Mark. Potential role of daratumumab in the treatment of multiple
myeloma. Onco Targets Ther. 2014; 7: 1095–1100.

Company Announcement no. 19
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark